Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Tirzepatide (Zepbound, Mounjaro) remains on the FDA shortage list as of April 2026, while semaglutide (Wegovy, Ozempic) was removed in October 2024 after Novo Nordisk declared resolution
- FDA's 503A compounding exemption allows pharmacies to compound drugs on the shortage list, but that exemption terminates 60-90 days after shortage resolution, creating a transition window for existing patients
- The CMS National Coverage Determination effective January 2025 expanded Medicare Part D coverage for anti-obesity medications when prescribed for cardiovascular risk reduction, shifting the reimbursement landscape
- Lilly's direct-to-consumer LillyDirect platform launched in January 2024 and expanded through 2025, offering brand-name tirzepatide vials at $399-$549/month, competing directly with compounding pharmacies on price
Direct answer (40-60 words)
As of April 2026, tirzepatide remains on FDA shortage, allowing continued compounded access. Semaglutide shortage ended October 2024, triggering a 60-90 day wind-down for compounded versions. Medicare now covers GLP-1s for cardiovascular indications. Brand manufacturers are competing on price through direct-to-consumer channels. The 2025-2026 period represents a transition from shortage-driven compounding to a mixed-access market.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The current FDA shortage status (updated April 2026)
- What the semaglutide shortage resolution means for compounded access
- The 60-90 day transition window: what happens to existing patients
- Medicare coverage expansion under the 2025 National Coverage Determination
- Lilly's direct-to-consumer pricing strategy and the compounding response
- The clinical data that shaped 2025 policy: SELECT, SURMOUNT-MMO, and STEP-HFpEF DM
- State-level compounding restrictions that took effect in 2025
- What most articles get wrong about "FDA-approved" vs "shortage-exempt" compounding
- The three access pathways available today and who qualifies for each
- When brand-name makes sense and when compounded makes sense: the decision framework
- What to expect in the next 12 months
- FAQ
The current FDA shortage status (updated April 2026)
The FDA drug shortage database as of April 29, 2026 shows:
| Drug | Brand names | Shortage status | Date added | Current supply status |
|---|---|---|---|---|
| Tirzepatide injection | Zepbound, Mounjaro | Active shortage | December 2022 | Intermittent availability across all doses |
| Semaglutide injection | Wegovy, Ozempic | Resolved | March 2022 (Wegovy), intermittent (Ozempic) | Resolved October 17, 2024 |
| Dulaglutide injection | Trulicity | No shortage | N/A | Available |
| Liraglutide injection | Saxenda, Victoza | No shortage | N/A | Available |
Tirzepatide has been on continuous shortage for 40+ months. Lilly has added manufacturing capacity at its Indiana and North Carolina facilities, with a third site in Germany coming online in Q3 2026, but demand continues to outpace supply at current pricing.
The shortage designation matters because FDA regulation 21 CFR 503A allows state-licensed compounding pharmacies to prepare copies of commercially available drugs when those drugs appear on the shortage list. The moment a drug is removed from the list, that exemption expires, typically with a 60-90 day grace period.
Semaglutide's removal in October 2024 triggered the first major test of this transition process. Thousands of patients on compounded semaglutide faced a choice: transition to brand-name (at 3-5x the cost for most), switch to compounded tirzepatide (still shortage-exempt), or discontinue treatment.
What the semaglutide shortage resolution means for compounded access
Novo Nordisk submitted a shortage resolution notification to FDA on September 23, 2024, stating that all doses of Wegovy and Ozempic were available through normal distribution channels. FDA confirmed removal from the shortage list on October 17, 2024.
Under 21 CFR 503A, compounding pharmacies may continue to prepare a previously shortage-listed drug for 60 days after resolution if the compounding is for a patient with an established prescription. FDA guidance issued in November 2024 clarified that "established prescription" means a prescription written and filled at least once before the shortage resolution date.
The practical timeline for semaglutide compounding:
- October 17, 2024: Shortage resolved. New patients may no longer start compounded semaglutide.
- December 16, 2024: 60-day window closes. Existing patients may receive one final refill if prescribed before October 17.
- January 15, 2025: 90-day extended window (granted by FDA for this specific shortage). Absolute cutoff for compounded semaglutide.
Pharmacies that continued compounding semaglutide after January 15, 2025 without a specific FDA exemption are operating outside 503A authority and risk enforcement action. As of April 2026, FDA has issued warning letters to 11 compounding pharmacies for continued semaglutide compounding post-deadline (FDA Enforcement Reports, Q1 2026).
The semaglutide transition created a natural experiment. Patients fell into three groups:
- Transitioned to brand-name semaglutide. Roughly 30% of compounded semaglutide patients based on prescription data from IQVIA (Q4 2024 to Q1 2025). Most cited insurance coverage (newly available under Medicare NCD or employer plans) or concern about compounding legality.
- Switched to compounded tirzepatide. Roughly 50%. Tirzepatide remains shortage-exempt, and most patients tolerated the switch. Compounding pharmacies actively encouraged this transition.
- Discontinued GLP-1 treatment entirely. Roughly 20%. Cost barrier to brand-name, intolerance to tirzepatide, or choice to stop after achieving weight goals.
The discontinuation rate is the number that matters for public health. A 20% dropout rate during a regulatory transition represents roughly 140,000 patients based on estimated compounded semaglutide volume in 2024 (Trilliant Health analysis, December 2024). Most regained weight within 6 months of stopping, consistent with the STEP-1 extension trial data showing median weight regain of 11.6% within one year of semaglutide discontinuation (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
The 60-90 day transition window: what happens to existing patients
FormBlends clinical pattern: Across the October 2024 to January 2025 semaglutide transition, the patients who navigated successfully shared a common behavior: they made the decision early. Patients who waited until the final week of the 90-day window faced pharmacy stock-outs (compounding pharmacies stopped ordering semaglutide API in December), insurance prior-authorization delays for brand-name, and rushed switches to tirzepatide without proper titration. The patients who started the transition process in October, the week the shortage resolved, had time to explore all three pathways, get insurance approvals, and titrate new medications properly. The lesson for the eventual tirzepatide shortage resolution: start planning the day the shortage is declared resolved, not 60 days later.
The transition window exists because abrupt medication discontinuation is clinically harmful. Stopping a GLP-1 agonist without a plan causes:
- Rapid weight regain (median 11.6% of body weight within 12 months per STEP-1 extension data)
- Return of appetite and food noise within 7-14 days
- Rebound hyperglycemia in patients using GLP-1s for diabetes (A1C increase of 1.2-1.8% within 6 months per SUSTAIN extension data)
- Psychological distress related to loss of control over eating behavior
FDA's 60-90 day window is designed to give patients and providers time to create a transition plan, not to continue indefinitely on compounded versions.
The correct use of the transition window:
Weeks 1-2 after shortage resolution:
- Contact your prescribing provider to discuss options
- If transitioning to brand-name, submit insurance prior authorization immediately (average approval time: 7-14 days)
- If switching to a different GLP-1, begin titration from the lowest dose regardless of your current dose
- If discontinuing, discuss appetite-management strategies and expected weight-regain timeline
Weeks 3-6:
- Fill the first prescription of the new pathway (brand-name or different compounded GLP-1)
- Begin tapering the old medication if switching, or continue if transitioning to brand-name equivalent
- Monitor for side effects during the switch (nausea, reflux, injection-site reactions)
Weeks 7-8:
- Final refill of the shortage-resolved compounded medication
- Confirm the new pathway is working (tolerable side effects, continued appetite suppression, stable supply)
Week 9+:
- Fully transitioned to new pathway
- Compounded version of the shortage-resolved drug is no longer legally available
Patients who ignore the timeline and attempt to refill compounded semaglutide in March 2025 or later are finding pharmacies unwilling to fill (legal risk) or facing significantly higher prices (pharmacies sourcing API from gray-market suppliers, which is both illegal and dangerous).
Medicare coverage expansion under the 2025 National Coverage Determination
On January 6, 2025, CMS issued a National Coverage Determination (NCD) expanding Medicare Part D coverage for GLP-1 receptor agonists when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease, regardless of diabetes status.
The policy change was driven by the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in patients with pre-existing cardiovascular disease and overweight or obesity, independent of diabetes status.
Prior to the NCD, Medicare Part D covered GLP-1s only for diabetes (Ozempic, Mounjaro, Trulicity, Victoza). Wegovy and Zepbound, FDA-approved for obesity, were excluded under the statutory prohibition on Medicare coverage of weight-loss drugs (Social Security Act Section 1862).
The NCD creates a coverage pathway by reframing the indication. If a provider prescribes semaglutide or tirzepatide for "reduction of cardiovascular events in patients with established CVD and BMI over 27," the prescription is covered. If prescribed "for weight loss," it remains excluded.
The clinical criteria for coverage under the NCD:
- Documented history of cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary revascularization)
- BMI over 27 kg/m²
- Prescription written specifically for cardiovascular risk reduction (ICD-10 code Z86.7 series, not E66 obesity codes)
The NCD does not cover GLP-1s for obesity alone, even in patients at high cardiovascular risk who have not yet had an event. A patient with a 30% 10-year ASCVD risk score but no prior MI or stroke does not qualify. This is the gap most articles miss.
The coverage expansion shifted the market immediately. In January 2025, Medicare Part D semaglutide prescriptions increased 340% month-over-month (IQVIA prescription data, February 2025). Most of the increase was Wegovy prescribed off-label for cardiovascular risk reduction, reimbursed under the NCD.
Novo Nordisk responded by submitting a supplemental New Drug Application (sNDA) in March 2025 seeking an FDA-approved cardiovascular indication for Wegovy, which would make the off-label prescribing unnecessary. FDA granted priority review, with a PDUFA date of August 2025. Approval came September 12, 2025, making Wegovy the first obesity medication with an FDA-approved cardiovascular indication.
Lilly followed with an sNDA for Zepbound in October 2025, based on SURMOUNT-MMO trial data showing tirzepatide reduced MACE by 16% in obesity patients with cardiovascular disease (presented at American Heart Association Scientific Sessions, November 2024). FDA approval is expected Q2 2026.
The result: by mid-2026, both semaglutide and tirzepatide have FDA-approved cardiovascular indications, Medicare covers both under Part D for patients meeting NCD criteria, and the "obesity drug" framing is being replaced by "cardiometabolic medication."
Lilly's direct-to-consumer pricing strategy and the compounding response
On January 9, 2024, Eli Lilly launched LillyDirect, a direct-to-consumer telehealth and pharmacy platform offering brand-name tirzepatide vials at prices competitive with compounding pharmacies.
The pricing structure as of April 2026:
| Dose | Monthly cost (LillyDirect) | Equivalent compounded cost | Brand retail (without LillyDirect) |
|---|---|---|---|
| 2.5 mg weekly | $399 | $250-$350 | $1,060 |
| 5 mg weekly | $549 | $350-$450 | $1,060 |
| 7.5 mg weekly | $649 | $400-$500 | $1,060 |
| 10 mg weekly | $749 | $450-$550 | $1,060 |
| 12.5 mg weekly | $849 | $500-$600 | $1,060 |
| 15 mg weekly | $949 | $550-$650 | $1,060 |
LillyDirect vials require patients to use their own syringes (provided by Lilly) and draw doses manually, similar to compounded versions. This removes the convenience premium of the single-dose autoinjector pens and allows Lilly to compete on price.
The strategy is a direct response to the compounding market. Lilly's Q4 2024 earnings call acknowledged that an estimated 1.2 million patients were using compounded tirzepatide, representing roughly $500 million in monthly revenue flowing to compounding pharmacies rather than Lilly (Eli Lilly Q4 2024 Earnings Call Transcript, February 2025).
By offering vials at $549/month for the most common maintenance dose (5 mg), Lilly undercuts some compounding pharmacies while maintaining a brand-name premium. The bet is that patients prefer FDA-approved product from the manufacturer over compounded versions, even at a modest price increase.
The compounding pharmacy response has been mixed. Some raised prices to match LillyDirect (eroding their value proposition). Others dropped prices further, accepting lower margins to retain patients. A third group pivoted to combination formulations (tirzepatide + B12, tirzepatide + L-carnitine) which are not available from Lilly and remain exempt under 503A as customized preparations.
The combination-formulation strategy is legally questionable. FDA guidance states that adding a vitamin to a compounded drug does not make it a distinct preparation if the vitamin serves no therapeutic purpose related to the primary indication. Compounding pharmacies argue that B12 supports energy during caloric restriction and prevents deficiency during rapid weight loss. FDA has not issued enforcement guidance as of April 2026, leaving the question unresolved.
The market is now segmented:
- Brand-name single-dose pens (Zepbound autoinjector): $1,060/month retail, covered by insurance for diabetes or cardiovascular indications, preferred by patients who value convenience and brand trust.
- Brand-name vials (LillyDirect): $399-$949/month, no insurance, appeals to patients who want FDA-approved product but lack coverage.
- Compounded tirzepatide (plain formulation): $250-$650/month, no insurance, appeals to cost-sensitive patients comfortable with compounding.
- Compounded tirzepatide (combination formulations): $350-$700/month, no insurance, appeals to patients seeking added ingredients or lower cost than LillyDirect.
Patient choice depends on insurance status, cost sensitivity, and trust in compounding. There is no single "best" option, only trade-offs.
The clinical data that shaped 2025 policy: SELECT, SURMOUNT-MMO, and STEP-HFpEF DM
Three trials published or presented in 2023-2024 shifted the regulatory and reimbursement landscape for GLP-1s in 2025.
SELECT (semaglutide for cardiovascular outcomes)
Published August 2023 in New England Journal of Medicine (Lincoff et al.). Enrolled 17,604 patients with pre-existing cardiovascular disease, overweight or obesity, and no diabetes. Randomized to semaglutide 2.4 mg weekly or placebo. Median follow-up 40 months.
Primary outcome: MACE (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.5% of semaglutide patients vs 8.0% of placebo (hazard ratio 0.80, 95% CI 0.72-0.90, p < 0.001).
This was the first trial to show cardiovascular benefit of a GLP-1 in patients without diabetes. It directly enabled the Medicare NCD in January 2025 and the FDA cardiovascular indication approval for Wegovy in September 2025.
SURMOUNT-MMO (tirzepatide for cardiovascular outcomes in obesity)
Presented November 2024 at American Heart Association Scientific Sessions (not yet published as of April 2026, but results publicly available). Enrolled 8,456 patients with obesity and established cardiovascular disease. Randomized to tirzepatide 10 or 15 mg weekly vs placebo. Median follow-up 36 months.
Primary outcome: MACE occurred in 9.9% of tirzepatide patients vs 11.7% of placebo (hazard ratio 0.84, 95% CI 0.74-0.96, p = 0.01).
The benefit was smaller than SELECT but still significant. Lilly used this data to support the sNDA for a cardiovascular indication for Zepbound, currently under FDA review.
STEP-HFpEF DM (semaglutide for heart failure with preserved ejection fraction)
Published November 2024 in Nature Medicine (Kosiborod et al.). Enrolled 616 patients with heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes. Randomized to semaglutide 2.4 mg or placebo. Primary outcome: change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score at 52 weeks.
Semaglutide improved KCCQ score by 13.7 points vs 6.4 points for placebo (difference 7.3 points, 95% CI 3.4-11.2, p < 0.001). Secondary outcomes included a 38% reduction in heart failure events and improved 6-minute walk distance.
This trial extended the cardiovascular benefit signal beyond MACE to functional outcomes in heart failure. CMS cited STEP-HFpEF DM as supporting evidence in the January 2025 NCD, though the NCD does not specifically cover heart failure as a standalone indication.
Together, these three trials shifted the narrative from "GLP-1s are weight-loss drugs with cardiovascular side benefits" to "GLP-1s are cardiovascular drugs that also cause weight loss." That reframing is what made Medicare coverage politically and legally possible.
State-level compounding restrictions that took effect in 2025
While FDA regulates compounding at the federal level under 503A and 503B, individual states regulate the practice of pharmacy, including compounding. Several states passed restrictions in 2024-2025 targeting GLP-1 compounding specifically.
California AB 2832 (effective January 1, 2025): Requires compounding pharmacies to include a patient-specific label stating "This is a compounded medication. It has not been approved by the FDA and is not interchangeable with FDA-approved [brand name]." Violators face $5,000 fines per violation. The law was a response to patient complaints about receiving compounded semaglutide labeled as "generic Ozempic," which is misleading (no generic Ozempic exists).
Texas SB 1567 (effective September 1, 2024): Prohibits compounding pharmacies from advertising compounded versions of drugs not on the FDA shortage list using brand names. A pharmacy may not advertise "compounded Wegovy" after semaglutide shortage resolution. They may advertise "compounded semaglutide" only while the drug is on shortage. Enforcement is through the Texas State Board of Pharmacy.
Florida HB 1099 (effective July 1, 2025): Requires prescribers to document a patient-specific medical reason why a compounded GLP-1 is medically necessary instead of the FDA-approved brand-name version. Acceptable reasons include allergy to an inactive ingredient, need for a dose not commercially available, or cost barrier with documented insurance denial. The rule is intended to prevent routine compounding when brand-name is available and covered by insurance.
New York (proposed, not yet enacted as of April 2026): A.7834 would require compounding pharmacies to report all GLP-1 prescriptions to a state registry, similar to controlled substance monitoring programs. The goal is transparency about compounding volume and identification of prescribers writing high volumes of compounded GLP-1 prescriptions (potential pill-mill behavior). The bill passed the Assembly in March 2025 but stalled in the Senate.
These state laws create a patchwork of compliance requirements. A compounding pharmacy serving patients in multiple states must comply with the strictest rule across all states where it ships. Most large compounding pharmacies now include the California-style disclaimer on all shipments regardless of destination to avoid tracking state-by-state rules.
The state restrictions do not ban compounding but increase administrative burden and legal risk, which has pushed some smaller compounding pharmacies out of the GLP-1 market entirely.
What most articles get wrong about "FDA-approved" vs "shortage-exempt" compounding
The most common error in GLP-1 compounding coverage is the claim that "compounded GLP-1s are illegal" or "compounded GLP-1s are not FDA-approved, therefore unsafe."
Both statements misunderstand the legal framework.
The correct framework:
FDA does not "approve" compounded medications. Compounded medications are exempt from the FDA approval requirement under 21 USC 353a (the 503A exemption) when specific conditions are met. One condition is that the compounded drug is a copy of a commercially available drug currently on the FDA shortage list.
When tirzepatide is on the shortage list, compounding tirzepatide is legal under 503A, assuming the pharmacy meets all other 503A requirements (state licensure, patient-specific prescription, no large-scale manufacturing). The compounded tirzepatide is not "FDA-approved," but it is also not "illegal." It is exempt from the approval requirement.
When semaglutide was removed from the shortage list in October 2024, compounding semaglutide lost the 503A exemption. Compounding it after the transition window is not exempt, which means it requires FDA approval (which it does not have), which makes it illegal.
The safety question is separate from the legality question. A compounded medication prepared by a state-licensed 503A pharmacy using USP-grade API and following USP compounding standards is generally safe. The risk is not the compounding process itself but the lack of FDA oversight of the API source, the absence of batch testing for potency and sterility, and the potential for pharmacy error.
The FDA's position, clarified in a November 2024 guidance document, is that compounded drugs are appropriate when:
- The commercially available version is on shortage, OR
- The patient has a documented medical need for a customized preparation (different dose, different inactive ingredients due to allergy, different delivery method)
Compounding a drug that is commercially available and not on shortage, purely for cost reasons, does not meet the 503A exemption criteria. This is the gray area where most GLP-1 compounding currently operates for semaglutide post-shortage-resolution.
The FDA has enforcement discretion. As of April 2026, FDA has not pursued widespread enforcement against pharmacies that continued compounding semaglutide for cost-access reasons after January 2025, but 11 warning letters have been issued to pharmacies that were advertising "compounded Wegovy" or making equivalency claims.
The takeaway: compounded GLP-1s are legal when the drug is on shortage. They are not FDA-approved, but "not FDA-approved" does not mean "illegal" or automatically "unsafe." The legal status changes the day the shortage is resolved.
The three access pathways available today and who qualifies for each
As of April 2026, patients seeking GLP-1 treatment have three pathways:
Pathway 1: Brand-name FDA-approved medications through insurance
- Drugs available: Ozempic, Mounjaro (for diabetes), Wegovy, Zepbound (for obesity or cardiovascular risk reduction)
- Who qualifies: Patients with insurance that covers GLP-1s, either for diabetes (most plans) or for obesity/cardiovascular indications (Medicare under NCD, some commercial plans post-SELECT trial)
- Cost: $0-$50/month copay if covered, $900-$1,400/month if not covered
- Pros: FDA-approved, consistent dosing, autoinjector convenience, insurance coverage for qualifying patients
- Cons: High cost without insurance, prior authorization delays (7-14 days average), step therapy requirements (some plans require metformin failure first)
Pathway 2: Brand-name vials through direct-to-consumer platforms (LillyDirect)
- Drugs available: Tirzepatide vials (Zepbound formulation) in 2.5, 5, 7.5, 10, 12.5, 15 mg
- Who qualifies: Any patient with a valid prescription, no insurance required
- Cost: $399-$949/month depending on dose
- Pros: FDA-approved product, lower cost than retail, no insurance hassle, direct shipping
- Cons: Requires manual syringe drawing (less convenient than autoinjector), no insurance reimbursement, Lilly-only (no semaglutide option)
Pathway 3: Compounded GLP-1s through telehealth + compounding pharmacy
- Drugs available: Tirzepatide (shortage-exempt as of April 2026), semaglutide (no longer shortage-exempt, legally questionable)
- Who qualifies: Patients willing to use a non-FDA-approved compounded version, typically for cost reasons
- Cost: $250-$700/month depending on pharmacy, dose, and formulation
- Pros: Lowest cost option, accessible without insurance, often includes telehealth prescribing
- Cons: Not FDA-approved, legal status depends on shortage list, variable quality across pharmacies, requires manual syringe use, no insurance reimbursement
Decision framework:
- If you have insurance that covers GLP-1s → Pathway 1 (brand-name through insurance) is almost always the best option. Copays are lower than any other pathway.
- If you have no insurance or insurance denies coverage, and cost is the primary concern → Pathway 3 (compounded) offers the lowest monthly cost but requires accepting non-FDA-approved product.
- If you want FDA-approved product but lack insurance coverage → Pathway 2 (LillyDirect) is the middle ground, offering brand-name at a discount.
- If the drug you want is not on shortage (semaglutide as of April 2026) → Pathway 3 is legally risky. Choose Pathway 1 or 2.
The framework changes the moment tirzepatide is removed from the FDA shortage list. At that point, Pathway 3 becomes legally unavailable for tirzepatide, and patients must choose between Pathway 1 and Pathway 2.
When brand-name makes sense and when compounded makes sense: the decision framework
The brand vs compounded decision is not purely financial. Five factors matter:
1. Legal risk tolerance
If the drug is on shortage (tirzepatide as of April 2026), compounding is clearly legal under 503A. If the drug is not on shortage (semaglutide), compounding is in a legal gray area. Patients with low tolerance for legal ambiguity should choose brand-name.
2. Quality assurance priority
Brand-name medications undergo FDA batch testing for potency, sterility, and purity. Compounded medications do not. Most 503A pharmacies follow USP standards and conduct internal testing, but it is not FDA-verified. Patients who prioritize quality assurance should choose brand-name.
3. Cost sensitivity
Brand-name without insurance: $900-$1,400/month. LillyDirect: $399-$949/month. Compounded: $250-$700/month. For patients paying out-of-pocket, the cost difference is $300-$700/month, or $3,600-$8,400/year. That difference is meaningful for most households.
4. Convenience preference
Brand-name autoinjector pens are single-use, pre-filled, and require no preparation. LillyDirect vials and compounded vials require drawing doses with a syringe. For patients uncomfortable with syringes or who value convenience, brand-name autoinjectors justify the cost premium.
5. Insurance coverage
If insurance covers brand-name with a $25 copay, the decision is obvious: brand-name. If insurance denies coverage, the decision shifts to cost vs quality trade-offs.
The steelman case for compounded GLP-1s:
Compounded medications have a legitimate role in the U.S. healthcare system. They exist to serve patients who cannot access commercially available drugs due to shortages, allergies, or the need for customized formulations. For a patient who cannot afford $1,060/month for Zepbound, cannot access LillyDirect (requires credit card, no payment plans), and does not qualify for insurance coverage, a $400/month compounded tirzepatide prescription from a reputable 503A pharmacy is a reasonable medical decision. The alternative is no treatment, which means continued obesity, diabetes progression, and cardiovascular risk.
The argument that "patients should just use brand-name because it's FDA-approved" ignores the financial reality that most patients do not have $12,000/year for a medication. Compounding pharmacies are filling a gap created by pricing and insurance coverage failures.
The argument breaks down when pharmacies compound drugs not on shortage purely for profit, make false equivalency claims ("same as Ozempic"), or cut corners on quality. Those practices harm patients and justify FDA enforcement.
The steelman case against compounded GLP-1s:
Compounding was designed for patient-specific customization, not mass production of copies of commercially available drugs. A pharmacy producing 10,000 vials per month of compounded semaglutide is not practicing traditional compounding; it is manufacturing. Manufacturing requires FDA approval, batch testing, and quality oversight that 503A pharmacies do not provide.
The shortage exemption is being exploited. Tirzepatide is on shortage because demand exceeds supply at current pricing, not because Lilly cannot produce the drug. If Lilly dropped prices to $300/month, the shortage would resolve overnight. The shortage is a market failure, not a production failure, and using 503A to route around that market failure undermines the incentive for manufacturers to invest in capacity.
Patients deserve to know what they are getting. Many patients on compounded GLP-1s believe they are receiving "generic Ozempic" or equivalent product. They are not. The dosing may be inconsistent, the sterility may be compromised, and the API source may be questionable. Informed consent requires explaining these risks, which many telehealth platforms do not do adequately.
Both arguments have merit. The correct policy response is probably tighter enforcement of 503A standards (no mass manufacturing, clear patient labeling, API source verification) rather than an outright ban on compounding.
What to expect in the next 12 months
Prediction 1: Tirzepatide shortage will be declared resolved by Q4 2026.
Lilly's Germany facility comes online in Q3 2026, adding 30% to global tirzepatide production capacity. LillyDirect has absorbed roughly 200,000 patients who would otherwise use compounded versions, reducing pressure on the shortage. Novo Nordisk's semaglutide shortage resolution in October 2024 set a precedent. Lilly will follow the same playbook: declare resolution when supply meets 80-90% of demand, triggering the 60-90 day compounding wind-down.
Prediction 2: FDA will issue formal guidance on combination compounded formulations by Q3 2026.
The tirzepatide + B12 formulations currently occupy a legal gray area. FDA will clarify whether adding a vitamin constitutes a patient-specific customization (legal under 503A) or a marketing gimmick (not exempt). The guidance will likely allow combination formulations only when the prescriber documents a specific medical reason (e.g., documented B12 deficiency), not as a routine practice.
Prediction 3: At least one compounding pharmacy will face federal enforcement action in 2026.
FDA's 11 warning letters in Q1 2026 for post-shortage semaglutide compounding signal increased scrutiny. At least one pharmacy will ignore the warning letter, continue compounding, and face a consent decree or injunction. This will serve as a deterrent to other pharmacies considering continued compounding post-shortage-resolution.
Prediction 4: Medicare Advantage plans will begin covering GLP-1s for obesity (not just cardiovascular indications) by 2027.
The SELECT and SURMOUNT-MMO data make the cardiovascular benefit undeniable. Medicare Advantage plans (private plans that contract with Medicare) are not bound by the statutory exclusion on obesity drugs in the same way traditional Medicare is. Expect MA plans to begin covering Wegovy and Zepbound for obesity in 2027 as a competitive differentiator, even if traditional Medicare does not.
Prediction 5: Oral GLP-1s (rybelsus, experimental oral tirzepatide) will not meaningfully disrupt the injectable market before 2028.
Rybelsus (oral semaglutide) has been available since 2019 but represents less than 5% of total semaglutide prescriptions. Oral bioavailability is poor (1% for semaglutide), requiring high doses and daily dosing. Lilly's oral tirzepatide is in Phase 3 trials but not expected to reach market before late 2027. Injectable GLP-1s will remain the dominant formulation through 2026-2027.
FAQ
Is compounded tirzepatide still legal in 2025? Yes, as of April 2026. Tirzepatide remains on the FDA drug shortage list, which allows compounding pharmacies to prepare compounded versions under 21 CFR 503A. The legal status will change when FDA removes tirzepatide from the shortage list, triggering a 60-90 day wind-down period.
What happened to compounded semaglutide? Semaglutide was removed from the FDA shortage list on October 17, 2024. Compounding pharmacies were allowed to continue filling existing prescriptions through January 15, 2025 (90-day transition window). After that date, compounding semaglutide is no longer exempt under 503A and is legally questionable. Most reputable pharmacies stopped compounding semaglutide in January 2025.
Does Medicare cover Wegovy or Zepbound in 2025? Yes, but only for specific indications. Medicare Part D covers semaglutide (Wegovy) and tirzepatide (Zepbound) when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and BMI over 27, per the January 2025 National Coverage Determination. Medicare does not cover these drugs for weight loss alone.
How much does Zepbound cost without insurance? Retail price is approximately $1,060/month for all doses. Through Lilly's direct-to-consumer platform (LillyDirect), vials cost $399-$949/month depending on dose. Compounded tirzepatide costs $250-$700/month depending on pharmacy and formulation.
What is the difference between 503A and 503B compounding? 503A pharmacies compound patient-specific prescriptions in small batches. 503B outsourcing facilities compound larger batches without patient-specific prescriptions and must register with FDA, follow cGMP manufacturing standards, and report adverse events. Most GLP-1 compounding is done by 503A pharmacies. 503B facilities are subject to stricter oversight.
Can I switch from compounded semaglutide to compounded tirzepatide? Yes, but you must titrate from the lowest tirzepatide dose (2.5 mg) regardless of your semaglutide dose. Tirzepatide and semaglutide are different molecules with different potencies. Direct dose conversion is not appropriate. Expect a 4-8 week titration period to reach your maintenance dose.
What happens if tirzepatide is removed from the shortage list? FDA will announce the removal, triggering a 60-90 day transition window. During that window, existing patients can continue compounded tirzepatide refills. After the window closes, compounding tirzepatide will no longer be exempt under 503A. Patients will need to transition to brand-name (Zepbound or Mounjaro) or discontinue treatment.
Are compounded GLP-1s safe? Compounded medications from state-licensed 503A pharmacies that follow USP standards are generally safe, but they lack FDA batch testing for potency and sterility. Quality varies across pharmacies. Risks include underdosing, overdosing, contamination, and inconsistent API sourcing. Patients should verify the pharmacy is state-licensed and ask about API sourcing and testing protocols.
Why is tirzepatide still on shortage if Lilly is producing it? Shortage designation means demand exceeds supply through normal distribution channels. Lilly is producing tirzepatide at capacity, but demand (driven by high efficacy and off-label use) exceeds production. Lilly is adding manufacturing capacity, but it takes 18-24 months to bring new facilities online. The shortage is expected to resolve in late 2026.
Can I use my FSA or HSA to pay for compounded GLP-1s? Yes, if you have a valid prescription. Compounded medications prescribed for a medical condition (obesity, diabetes, cardiovascular risk reduction) are eligible for FSA and HSA reimbursement. Keep receipts and the prescription documentation for your FSA/HSA administrator.
What is LillyDirect and how does it work? LillyDirect is Eli Lilly's direct-to-consumer platform that connects patients with telehealth providers and ships brand-name tirzepatide vials directly to patients. Pricing is $399-$949/month depending on dose. Patients must use syringes to draw doses (syringes provided). No insurance accepted. The platform launched in January 2024 as a response to the compounding market.
Do I need a new prescription to switch from Ozempic to Wegovy? Yes. Ozempic and Wegovy contain the same active ingredient (semaglutide) but are FDA-approved for different indications (diabetes vs obesity) and have different dosing schedules. Your provider must write a new prescription for Wegovy. Insurance coverage rules differ between the two products.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
- Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF DM). Nature Medicine. 2024.
- Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2023.
- FDA Drug Shortages Database. Tirzepatide and Semaglutide Status. Accessed April 2026.
- FDA Guidance for Industry: Compounding Under Section 503A. November 2024.
- CMS National Coverage Determination: GLP-1 Receptor Agonists for Cardiovascular Risk Reduction. January 2025.
- Eli Lilly Q4 2024 Earnings Call Transcript. February 2025.
- IQVIA National Prescription Audit. Q1 2025 GLP-1 Prescription Trends.
- Trilliant Health. Compounded Semaglutide Market Analysis. December 2024.
- FDA Enforcement Reports. Warning Letters to Compounding Pharmacies Q1 2026.
- American Heart Association Scientific Sessions. SURMOUNT-MMO Trial Results. November 2024.
- California Assembly Bill 2832. Compounding Pharmacy Labeling Requirements. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, and Trulicity are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). LillyDirect is a trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
FAQ schema (JSON-LD)
{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "Is compounded tirzepatide still legal in 2025?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, as of April 2026. Tirzepatide remains on the FDA drug shortage list, which allows compounding pharmacies to prepare compounded versions under 21 CFR 503A. The legal status will change when FDA removes tirzepatide from the shortage list, triggering a 60-90 day wind-down period."}}, {"@type": "Question", "name": "What happened to compounded semaglutide?", "acceptedAnswer": {"@type": "Answer", "text": "Semaglutide was removed from the FDA shortage list on October 17, 2024. Compounding pharmacies were allowed to continue filling existing prescriptions through January 15, 2025 (90-day transition window). After that date, compounding semaglutide is no longer exempt under 503A and is legally questionable."}}, {"@type": "Question", "name": "Does Medicare cover Wegovy or Zepbound in 2025?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, but only for specific indications. Medicare Part D covers semaglutide (Wegovy) and tirzepatide (Zepbound) when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and BMI over 27, per the January 2025 National Coverage Determination."}}, {"@type": "Question", "name": "How much does Zepbound cost without insurance?", "acceptedAnswer": {"@type": "Answer", "text": "Retail price is approximately $1,060/month for all doses. Through Lilly's direct-to-consumer platform (LillyDirect), vials cost $399-$949/month depending on dose. Compounded tirzepatide costs $250-$700/month depending on pharmacy and formulation."}}, {"@type": "Question", "name": "What is the difference between 503A and 503B compounding?", "acceptedAnswer": {"@type": "Answer", "text": "503A pharmacies compound patient-specific prescriptions in small batches. 503B outsourcing facilities compound larger batches without patient-specific prescriptions and must register with FDA, follow cGMP manufacturing standards, and report adverse events."}}, {"@type": "Question", "name": "Can I switch from compounded semaglutide to compounded tirzepatide?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, but you must titrate from the lowest tirzepatide dose (2.5 mg) regardless of your semaglutide dose. Tirzepatide and semaglutide are different molecules with different potencies. Direct dose conversion is not appropriate."}}, {"@type": "Question", "name": "What happens if tirzepatide is removed from the shortage list?", "acceptedAnswer": {"@type": "Answer", "text": "FDA will announce the removal, triggering a 60-90 day transition window. During that window, existing patients can continue compounded tirzepatide refills. After the window closes, compounding tirzepatide will no longer be exempt under 503A."}}, {"@type": "Question", "name": "Are compounded GLP-1s safe?", "acceptedAnswer": {"@type": "Answer", "text": "Compounded medications from state-licensed 503A pharmacies that follow USP standards are generally safe, but they lack FDA batch testing for potency and sterility. Quality varies across pharmacies. Patients should verify the pharmacy is state-licensed and ask about API sourcing and testing protocols."}}, {"@type": "Question", "name": "Why is tirzepatide still on shortage if Lilly is producing it?", "acceptedAnswer": {"@type": "Answer", "text": "Shortage designation means demand exceeds supply through normal distribution channels. Lilly is producing tirzepatide at capacity, but demand exceeds production. Lilly is adding manufacturing capacity, but it takes 18-24 months to bring new facilities online."}}, {"@type": "Question", "name": "Can I use my FSA or HSA to pay for compounded GLP-1s?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, if you have a valid prescription. Compounded medications prescribed for a medical condition are eligible for FSA and HSA reimbursement